ALK and non-small cell lung carcinoma: Furthermore, encouraging early clinical results in NSCLC have demonstrated that ganetespib, a novel triazolone inhibitor of HSP90, may offer a potential strategy to target ALK inhibition by inducing substantial antitumor responses and overcoming acquired resistance in patients with ALK positive lung cancer.